NASDAQ · CGC
Healthcare · Drug Manufacturers - Specialty & Generic
$1.05
Up+$0.00 (+0.00%)
Updated Aug 22, 2026, 1:17 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CGC closed at $1.05 after 20 trading sessions, up 18.16% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $1.04 | $1.06 | $1.01 | $1.05 | 8.74M |
| Aug 19, 2026 | $0.99 | $1.05 | $0.9885 | $1.04 | 7.32M |
| Aug 18, 2026 | $0.9949 | $1.02 | $0.9873 | $0.9897 | 3.6M |
| Aug 17, 2026 | $1.00 | $1.035 | $0.9942 | $1.00 | 4.86M |
| Aug 14, 2026 | $1.01 | $1.02 | $0.9941 | $1.02 | 2.3M |
| Aug 13, 2026 | $1.03 | $1.05 | $1.00 | $1.01 | 4.49M |
| Aug 12, 2026 | $1.00 | $1.05 | $0.9906 | $1.025 | 7.79M |
| Aug 11, 2026 | $0.96 | $1.02 | $0.96 | $1.00 | 5.16M |
| Aug 10, 2026 | $0.9799 | $1.01 | $0.9405 | $0.9521 | 2.86M |
| Aug 7, 2026 | $0.99 | $1.02 | $0.97 | $0.9701 | 5.2M |
| Aug 6, 2026 | $0.933 | $0.95 | $0.9214 | $0.9322 | 1.74M |
| Aug 5, 2026 | $0.94 | $0.9442 | $0.915 | $0.9317 | 1.62M |
| Aug 4, 2026 | $0.95 | $0.9598 | $0.93 | $0.9313 | 2.08M |
| Aug 3, 2026 | $0.93 | $0.9595 | $0.9255 | $0.9577 | 3.05M |
| Jul 31, 2026 | $0.9106 | $0.92 | $0.8874 | $0.9173 | 2.04M |
| Jul 30, 2026 | $0.8798 | $0.918 | $0.87 | $0.918 | 2.44M |
| Jul 29, 2026 | $0.895 | $0.90 | $0.8632 | $0.8895 | 3.15M |
| Jul 28, 2026 | $0.9243 | $0.9307 | $0.889 | $0.8942 | 2.78M |
| Jul 27, 2026 | $0.90 | $0.947 | $0.8968 | $0.9243 | 2.1M |
| Jul 24, 2026 | $0.9043 | $0.9049 | $0.8834 | $0.8886 | 1.61M |
The latest Smart Investors Daily articles mentioning CGC.
CGC research
Company profile and research snapshot.
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 15, 2026 | ROTH CAPITAL PARTNERS | Buy | — |
| Jun 15, 2026 | ALLIANCE GLOBAL PARTNERS | Neutral | — |
| Jun 14, 2026 | CANACCORD GENUITY | Buy | — |
| Feb 8, 2026 | ATB CAPITAL MARKETS | Underperform | — |
| Dec 16, 2025 | ROTH CAPITAL PARTNERS | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 18, 2026
Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX:WEED) (NASDAQ:CGC) is pleased to announce that shareholders of MTL Cannabis Corp. ("MTL Cannabis" or "MTL") have voted to approve the Company's previously
Yahoo · Feb 12, 2026
The cannabis company's shares have plummeted by more than 40% over the past year.
Benzinga · Feb 12, 2026
Yahoo · Feb 11, 2026
CGC beats Q3 estimates as Canadian cannabis sales rise, but margin pressure and global volatility cloud its path to sustained profitability.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CGC.
